American Vanguard Corporation recently discussed its second quarter 2026 financial outcomes, highlighting a period characterized by a challenging agricultural landscape and fluctuating market dynamics. Despite a dip in overall net sales, the company underscored its strategic advancements in cost management, operational enhancements, and the acceleration of new product initiatives. Leadership expressed confidence in their ability to outperform competitors in the U.S. market and set clear objectives for future growth and profitability, including achieving double-digit EBITDA margins and substantial revenue targets.
During the second quarter of 2026, American Vanguard recorded net sales of $117 million, a reduction from $129 million in the corresponding period of 2025. This decrease was primarily influenced by an 18% fall in international sales, attributed to the severe El Nino weather conditions in Central America and regional labor disruptions. U.S. crop sales also experienced a 9% decline for the quarter, largely due to a shift in cotton product sales into the third quarter. However, the company's specialty business segment demonstrated robust growth, with revenues increasing by 11% for the quarter and 10% for the first half of 2026, driven by strong performance in OHP biological solutions and TER products.
Despite the top-line challenges, American Vanguard made significant strides in improving its operational efficiency. The first half of 2026 saw a 100 basis point improvement in gross margin, reaching 30%, compared to 29% in the prior year. This was achieved through various cost-saving measures, including a 3% reduction in operating expenses (excluding transformation costs) and the rationalization of the Los Angeles plant, which is expected to yield at least $4 million in annual savings. The company's adjusted EBITDA for the second quarter stood at $600,000, down from $11 million in Q2 2025, primarily due to lower volumes and manufacturing efficiencies. However, the first half adjusted EBITDA increased by over 20% to $17 million, up from $14 million in the first half of 2025.
American Vanguard is also heavily investing in its future growth trajectory. Research and Development spending increased by 12% year-over-year, supporting a strategic goal of launching 50 new products over the next five years, aiming for an additional $100 million in annualized revenue by 2030. The company anticipates achieving an annualized revenue run rate exceeding $600 million by the latter half of 2028, representing a 20% increase over 2025 levels. Management remains committed to debt reduction through diligent cash management, particularly emphasizing working capital discipline during peak seasonal needs, and plans to refinance its debt within the next two years.
The company's financial health remains a key focus, with inventory levels improving by $10 million to $181 million at quarter-end compared to Q2 2025. Net debt increased sequentially to $224.7 million, primarily due to seasonal working capital requirements. Looking ahead, American Vanguard projects its full fiscal year 2026 adjusted EBITDA to be between $44 million and $48 million, with revenue guidance set at $530 million to $550 million. These targets reflect the company's proactive measures to mitigate external market pressures and control internal operational factors, positioning it for sustained profitability and growth.
